Graft-versus-host disease (GVHD)
- Prevent with transplant-specific immunosuppression
- Systemic glucocorticoid is first-line for significant acute GVHD
- Steroid-refractory disease uses targeted immunomodulators
- Ruxolitinib is a key option
- Chronic GVHD therapy is organ- and severity-specific
- Infection prophylaxis/supportive care are integral
Use at a glance
- Prevent with transplant-specific immunosuppression
Escalation / refractory disease
- Systemic glucocorticoid is first-line for significant acute GVHD
- Steroid-refractory disease uses targeted immunomodulators
Treatment options
- Ruxolitinib is a key option
- Chronic GVHD therapy is organ- and severity-specific
Practical pearls
- Infection prophylaxis/supportive care are integral
Self-check
- What is first-line treatment for Graft-versus-host disease (GVHD)?
Systemic glucocorticoid.
- What is a key treatment approach for Graft-versus-host disease (GVHD)?
Ruxolitinib is a key option.
Drugs used for this (1)
All clinical uses · Open the interactive console ↗
